March 02, 2026

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

Conexiant

March 02, 2026

Sepsis Antibiotic Timing Shows Physician Divide

Emergency department physicians differ in how quickly they initiate antibiotics for suspected sepsis.

Conexiant

February 25, 2026

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

Patients with allergic fungal rhinosinusitis now have a targeted biologic option.

Conexiant

February 18, 2026

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Conexiant

February 17, 2026

FDA Broadens Pitolisant Label

The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

Conexiant

February 17, 2026

Retinal AI Predicts Neonatal Lung Disease

Retinal scans already performed in the NICU could flag infants at risk for serious lung disease before standard diagnosis

Conexiant

February 13, 2026

Chronic Cough Despite Normal Workup

Researchers describe diagnostic evaluation and management considerations when standard testing fails to identify the cause of persistent cough.

Conexiant

February 12, 2026

Drooling Flags Severe Dermatomyositis

Three cases suggest drooling may mark advanced dermatomyositis with dysphagia, aspiration pneumonia, and poor response to treatment.

Conexiant

February 12, 2026

Curbing Drug-Related Halitosis for Closer Moments

Individuals who have drug-related halitosis may need to take additional steps to prioritize oral health before intimate encounters.

Conexiant